DE68911397D1 - Radiohalogenierte Verbindungen für Markierung von spezifischen Stellen. - Google Patents

Radiohalogenierte Verbindungen für Markierung von spezifischen Stellen.

Info

Publication number
DE68911397D1
DE68911397D1 DE89401557T DE68911397T DE68911397D1 DE 68911397 D1 DE68911397 D1 DE 68911397D1 DE 89401557 T DE89401557 T DE 89401557T DE 68911397 T DE68911397 T DE 68911397T DE 68911397 D1 DE68911397 D1 DE 68911397D1
Authority
DE
Germany
Prior art keywords
radio
specific sites
halogenated compounds
radiohalogenated
marking specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE89401557T
Other languages
English (en)
Other versions
DE68911397T2 (de
Inventor
Daniel James Coughlin
Benjamin A Belinka
Vernon Leon Alvarez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytogen Corp
Original Assignee
Cytogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytogen Corp filed Critical Cytogen Corp
Application granted granted Critical
Publication of DE68911397D1 publication Critical patent/DE68911397D1/de
Publication of DE68911397T2 publication Critical patent/DE68911397T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Inks, Pencil-Leads, Or Crayons (AREA)
DE68911397T 1988-06-07 1989-06-06 Radiohalogenierte Verbindungen für Markierung von spezifischen Stellen. Expired - Fee Related DE68911397T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/203,793 US4966999A (en) 1988-06-07 1988-06-07 Radiohalogenated compounds for site specific labeling

Publications (2)

Publication Number Publication Date
DE68911397D1 true DE68911397D1 (de) 1994-01-27
DE68911397T2 DE68911397T2 (de) 1994-05-26

Family

ID=22755342

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68911397T Expired - Fee Related DE68911397T2 (de) 1988-06-07 1989-06-06 Radiohalogenierte Verbindungen für Markierung von spezifischen Stellen.

Country Status (9)

Country Link
US (1) US4966999A (de)
EP (1) EP0348261B1 (de)
JP (1) JPH02504643A (de)
AT (1) ATE98630T1 (de)
AU (1) AU3772889A (de)
CA (1) CA1318615C (de)
DE (1) DE68911397T2 (de)
ES (1) ES2062061T3 (de)
WO (1) WO1989011876A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5463080A (en) * 1992-08-27 1995-10-31 Bracco International B.V. 2,4,6-triiodo-1,3-benzenedicarboxylic acid compounds used as radiolabelling reagents
US5424402A (en) * 1993-10-18 1995-06-13 Board Of Trustees Of The University Of Kentucky Non-destructive method for radiolabelling biomolecules by halogenation
US6011021A (en) * 1996-06-17 2000-01-04 Guilford Pharmaceuticals Inc. Methods of cancer treatment using naaladase inhibitors
US5856106A (en) * 1995-11-01 1999-01-05 Biotransplant, Inc. Determination of antibody production against administered therapeutic glycoproteins, especially monoclonal antibodies
US6384022B1 (en) 1996-06-17 2002-05-07 Guilford Pharmaceuticals Inc. Prodrugs of NAALAdase inhibitors
US5824662A (en) * 1996-09-27 1998-10-20 Guilford Pharmaceuticals Inc. Treatment of global and focal ischemia using naaladase inhibitors
RU2218179C2 (ru) 1996-06-17 2003-12-10 Гилфорд Фармасьютикалз Инк. СПОСОБЫ ЛЕЧЕНИЯ РАКА С ПРИМЕНЕНИЕМ ИНГИБИТОРОВ NAALADазы
US6017903A (en) 1996-09-27 2000-01-25 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of treating a glutamate abnormality and effecting a neuronal activity in an animal using NAALADase inhibitors
US6071965A (en) * 1996-06-17 2000-06-06 Guilford Pharmaceuticals Inc. Phosphinic alkanoic acid derivatives
US5962521A (en) * 1997-04-04 1999-10-05 Guilford Pharmaceuticals Inc. Hydroxamic acid derivatives
CZ60499A3 (cs) 1996-09-27 1999-08-11 Guilford Pharmaceuticals Inc. Prostředky s účinkem na NAALADázy, způsoby léčení glutamátové abnormality a způsoby ovlivňování neuronální aktivity u živočichů
US5981209A (en) * 1997-12-04 1999-11-09 Guilford Pharmaceuticals Inc. Use of NAALADase activity to identify prostate cancer and benign prostatic hyperplasia
US6028216A (en) * 1997-12-31 2000-02-22 Guilford Pharmaceuticals Inc. Asymmetric syntheses and intermediates for preparing enantiomer-enriched hydroxyphosphinyl derivatives
US6129757A (en) * 1998-05-18 2000-10-10 Scimed Life Systems Implantable members for receiving therapeutically useful compositions
DE69927502T2 (de) 1998-07-06 2006-07-06 Mgi Gp, Inc. (N.D.Ges.D. Staates Delaware) Naaladase-hemmer anwendbar als pharmazeutische verbindungen und zusammensetzungen
US6265609B1 (en) 1998-07-06 2001-07-24 Guilford Pharmaceuticals Inc. Thio-substituted pentanedioic acid derivatives
US6395718B1 (en) 1998-07-06 2002-05-28 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
US6444657B1 (en) 1998-12-31 2002-09-03 Guilford Pharmaceuticals Inc. Methods for treating certain diseases using naaladase inhibitors
US6313159B1 (en) 1999-08-20 2001-11-06 Guilford Pharmaceuticals Inc. Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors
US20060198819A1 (en) * 2003-08-08 2006-09-07 Novo Nordisk Healthcare A/G Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
ES2521490T3 (es) * 2006-12-15 2014-11-12 Baxter International Inc. Conjugado de factor VIIa - ácido (poli)siálico con una vida media in vivo prolongada.
US8372380B2 (en) * 2007-03-30 2013-02-12 The Regents Of The University Of California In vivo imaging of sulfotransferases
SG10201401194VA (en) 2009-07-27 2014-07-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
KR101832937B1 (ko) * 2009-07-27 2018-02-28 박스알타 인코퍼레이티드 혈액 응고 단백질 복합체
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
ES2590679T3 (es) 2009-07-27 2016-11-23 Lipoxen Technologies Limited Glicopolisialilación de proteínas diferentes a proteínas de coagulación de la sangre
EA032056B1 (ru) 2010-12-22 2019-04-30 Баксалта Инкорпорейтид Конъюгат терапевтического белка и производного жирной кислоты, способы получения конъюгата терапевтического белка и производного жирной кислоты (варианты)
CN107922457B (zh) 2015-06-19 2022-05-13 森托瑞恩生物制药公司 用于控制药物释放的递送系统
MX2020005472A (es) 2017-11-30 2020-11-11 Centurion Biopharma Corp Sistemas de administración de fármacos a base de maitansinoide.
CN111712511B (zh) 2017-11-30 2024-07-16 拉德克斯公司 澳瑞他汀e衍生物的白蛋白结合产物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2808416A (en) * 1954-08-23 1957-10-01 Eastman Kodak Co Hydrazides of benzoic acid and derivatives thereof as antioxidants for fats and oils
US3809721A (en) * 1970-12-23 1974-05-07 Merck & Co Inc Substituted 2-aminomethyl-4,6-disubstituted phenols
DE2260933C3 (de) * 1972-12-08 1981-08-20 Schering Ag Berlin Und Bergkamen, 1000 Berlin Verfahren zur Herstellung von durch radioaktives Halogen markierten organischen Verbindungen
US3979506A (en) * 1974-10-11 1976-09-07 Pierce Chemical Company Radioactive compounds for labeling proteins
US4474746A (en) * 1980-08-08 1984-10-02 State University Of New York Diagnostic radiopharmaceuticals for localization in target tissues exhibiting a regional pH shift relative to surrounding tissues
US4450149A (en) * 1981-06-15 1984-05-22 Research Corporation Radiohalogenation method
US4430319A (en) * 1982-05-21 1984-02-07 State University Of New York Radioactive iodine labeled phenolic amines
DE3688103T2 (de) * 1985-05-17 1993-07-15 Neorx Corp Radiohalogenierte kleine molekuele fuer das markieren von proteinen.
US4764598A (en) * 1985-08-22 1988-08-16 The United States Of America As Represented By The Department Of Energy Precursors to radiopharmaceutical agents for tissue imaging

Also Published As

Publication number Publication date
DE68911397T2 (de) 1994-05-26
CA1318615C (en) 1993-06-01
EP0348261A1 (de) 1989-12-27
ATE98630T1 (de) 1994-01-15
AU3772889A (en) 1990-01-05
JPH02504643A (ja) 1990-12-27
WO1989011876A1 (en) 1989-12-14
EP0348261B1 (de) 1993-12-15
US4966999A (en) 1990-10-30
ES2062061T3 (es) 1994-12-16

Similar Documents

Publication Publication Date Title
DE68911397D1 (de) Radiohalogenierte Verbindungen für Markierung von spezifischen Stellen.
FI102017B (fi) Elektrokemoluminoivat analyysimenetelmät
FI852974L (fi) Nya n-hydroxylgruppen skyddande grupper och framstaellningsfoerfarande foer 3-acylamino-1-hydroxi-2-azetidinoner.
DE69021530D1 (de) Neue Derivate von A-nor-3-Carboxysteroiden.
FI906045A0 (fi) Kvaevehaltiga spirocykliska foereningar.
DE3887947D1 (de) Messanordnung von entfernungen.
BG31496A3 (en) Method for obtaining of 4- amino- 5- alkyl- sulphonyl ortoanizamid
IT7948485A0 (it) Analisi di prossimita' per scintillazione
TR22653A (tr) Yeralti formasyonu oezelliklerinin element logu alma islemiyle kantitatif tayini
FR2560728B1 (fr) Sonde ultrasonique de type-divise
BG41124A3 (en) Method for preparing benzamides
DK349288A (da) Immunometrisk bestemmelsesmetode for et antigent stof indeholdende mindst to antistofbindingssted er
GR1000664B (el) Παρασκευη ενωσεων αντι-υπερχοληστερολαιμικης τετραζολης και ενδιαμεσων αυτων.
KR880701561A (ko) 피브린에 대한 단클론의 항체
PT80268B (pt) Agulha de via ferrea
IT1223136B (it) Anticorpi monoclonali capaci di legarsi selettivamente alla doxorubicina ed analoghi e derivati
ATE61375T1 (de) Immunogenische konjugate und ihre verwendung in einer dihydropyridinprobe.
DE3588208D1 (de) Cephalosporinderivative
ES2064052T3 (es) Un compuesto de yodo radiactivo para marcar un anticuerpo.
IT8421358A0 (it) Derivato della ranitidina utile nel trattamento dell'ulcera.
ATE45147T1 (de) Azidobenzazepine.
FI873000A (fi) Substituoituja 1,2,3-tiadiatsoli-4-tiolaatteja
KR890013465U (ko) 창문 괘정장치
BG44031A3 (en) Method for preparing of cephalosporines
UA15922A1 (uk) СПОСІБ ОДЕРЖАHHЯ ЗАМІЩЕHИХ bЕtА-ДІКЕТОHІВ

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee